STAT

NOVEMBER 8, 2023

Vaccines work well to prevent cancers caused by the human papillomavirus (HPV). So well, in fact, that it may be time to review HPV screening protocols, according to the somewhat provocative conclusion of a new study examining the occurrence of genital HPV types eight years after immunization, published today in Cell Host & Microbe. The randomized control study included more than 60,000 women from 33 Finnish communities born in 1992, 1993, and 1994.

Vaccines 363

Vaccines Immunity Immunization 363

PharmaVoice

NOVEMBER 8, 2023

A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

Vaccines 148

Vaccines 148

STAT

NOVEMBER 8, 2023

Eli Lilly’s blockbuster drug tirzepatide, sold as Mounjaro for type 2 diabetes, has been cleared to treat obesity, making it the second in a highly effective class of weight loss medications to enter the market. The Food and Drug Administration’s long-awaited approval of the drug, which will be marketed under the name Zepbound for obesity, is a major milestone for Lilly.

Diabetes 363

Diabetes Drug Pricing 363

PharmaVoice

NOVEMBER 8, 2023

With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

148

148

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

NOVEMBER 8, 2023

When Ken Song was getting ready to leave his job as the CEO of a small biotech in 2020, he wasn’t sure what was next. But he knew one thing. “I deliberately said I’m not going to do oncology. Oncology is so crowded. Everybody thinks they have the solution, but the reality is, it’s all noise,” he said. That was until late March 2020, when he received two phone calls from two different investors, both pondering about the same thing: Was it possible to make more e

337

337

BioPharma Dive

NOVEMBER 8, 2023

A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

128

128

Pharma Times

NOVEMBER 8, 2023

Zoliflodacin inhibits the vital bacterial enzyme for bacterial function and reproduction - News - PharmaTimes

143

143

STAT

NOVEMBER 8, 2023

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan. “Would I have liked the stock market reaction to be more generous?

Drug Development 300

Drug Development 300

BioPharma Dive

NOVEMBER 8, 2023

The pharmaceutical company will sell the GLP-1 drug, branded as Zepbound, at a list price about 20% lower than Novo Nordisk's competing drug Wegovy.

Pharmaceutical Companies 117

Pharmaceutical Companies Pharmaceutical Companies 117

STAT

NOVEMBER 8, 2023

The therapy, an infusion of CAR-T cells designed to kill the lymphoma, was going well. Nearly a month after the treatment, the engineered cells had crushed the cancer, and the patient, a 49-year-old woman in the Netherlands, appeared to be cancer-free. But two weeks later, something was wrong. The patient couldn’t remember having been in the hospital or, indeed, ever being treated for lymphoma.

Hospitals 295

Hospitals 295

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmaState Academy

NOVEMBER 8, 2023

This is "not to be missed" Masterclass for Pharma Marketers! ???????????: To be awarded with 3CPhE (Continuing Pharma Education) points. Seats Booked: 14 / Seats Left 16 Registrations Open Limited Seats Interest Form For Next Batch We limit the number of participants in a batch so that high-quality interactive learning can happen. In case you have missed this batch, you can fill out the Interest form for the next batch.

Communication 105

Communication 105

STAT

NOVEMBER 8, 2023

WASHINGTON — With the prevalence of some chronic diseases trending up, the U.S. needs to revamp its approaches to preventative care and disease management, experts said at the Milken Future of Health Summit on Tuesday. Already, 6 in 10 Americans live with a chronic condition , and 4 in 10 live with at least two. Factors such as the U.S.’s aging population, delayed care during Covid-19, and the rising prevalence of obesity are only exacerbating the problem, said Karen Hacker, the Ce

Diabetes 294

Diabetes 294

PharmExec

NOVEMBER 8, 2023

Tirzepatide (Zepbound; Eli Lilly and Company) is expected to be available in the United States by the end of 2023 with a list price of $1,059.87.

115

115

STAT

NOVEMBER 8, 2023

Curie.Bio, the new biotech investment firm and incubator launched earlier this year by a group of industry veterans including Alexis Borisy and Zach Weinberg, has graduated its first startup. The startup, Forward Therapeutics, is coming out of the incubator with three drug candidates for chronic inflammatory disorders. It also just closed its first major financing round: a $50 million Series A round led by BVF Partners, with participation from RA Capital Management and OrbiMed.

284

284

Pharma Times

NOVEMBER 8, 2023

Communicable diseases account for 50% of all deaths in LMICs - News - PharmaTimes

Communication 142

Communication Vaccines 142

STAT

NOVEMBER 8, 2023

WASHINGTON — A prominent Senate panel on Wednesday passed a new package of health policy reforms that would rein in certain pharmacy middlemen practices and ensure Medicare patients aren’t paying more than insurers do for medications. The package passed the committee 26-0 with no amendments added. Sen. Ron Johnson (R-Wis.) didn’t vote.

Hospitals 275

Hospitals Packaging Drug Pricing 275

Outsourcing Pharma

NOVEMBER 8, 2023

Executive director of Medical Research Network's (MRN's) digital health, Edward Triebell, joined OSP for a Q&A where he shared some interesting shifts and statistics about digital trends in clinical research.

98

98

STAT

NOVEMBER 8, 2023

WASHINGTON — It’s easy to get people worked up about cures, but they don’t seem to be bothered by falling life expectancy, and Food and Drug Administration Commissioner Robert Califf would like to figure out how to connect the two. The United States has one of the lowest life expectancy rates among wealthy nations. Post-pandemic, the average American life span is down to 76.4 years.

256

256

Med Ed 101

NOVEMBER 8, 2023

Iron therapy can be life-changing for some anemia patients and help them improve their energy and ultimately, their quality of life. Sometimes anemia isn’t responsive to iron. In this article, I discuss my top reasons why patients don’t respond to iron therapy. Adherence When I consider reasons why patients don’t respond to iron, I always […] The post Reasons Why Patients Don’t Respond To Iron appeared first on Med Ed 101.

98

98

STAT

NOVEMBER 8, 2023

The Food and Drug Administration approved a surgical system used to reduce blood pressure from Recor Medical, the company announced Wednesday. The treatment, called renal denervation, is controversial in the cardiology community due to its unclear efficacy. Renal denervation is a treatment for patients who cannot manage standard doses of blood pressure medication — whether because the drugs aren’t effective enough for them, create overwhelming side effects, or become too cumbersome

240

240

Express Pharma

NOVEMBER 8, 2023

Biocon Biologics has entered into a definitive agreement with Eris Lifesciences (Eris) for the divesture of its dermatology and nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands. The transaction is a ‘Slump Sale’ that will enable a seamless transfer of the product brands and employees associated with these businesses.

Biosimilars 99

Biosimilars 99

STAT

NOVEMBER 8, 2023

The term “excited delirium” has been used for years by law enforcement and other first responders, including health care workers, to describe people who exhibit behavior that is considered “out of control.” This diagnosis has been applied again and again, even posthumously, as a justification for extreme, and sometimes deadly, interventions by law enforcement.

225

225

Express Pharma

NOVEMBER 8, 2023

Lupin announced the launch of Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials, after Lupin’s alliance partner Caplin Steriles (Caplin) received an approval for its ANDA from the United States Food and Drug Administration (US FDA). Rocuronium Bromide Injection, 50 mg/5 mL (10 mg/mL) and 100 mg/10 mL (10 mg/mL) Multiple-Dose Vials is the generic version of Zemuron Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA and is indicated for inpati

Inpatient 99

Inpatient 99

STAT

NOVEMBER 8, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello, everyone. Damian here with a close look at an en-vogue idea in oncology, an awkward welcome for a new CEO, and a twist on the classic drug pricing backlash.

Drug Pricing 220

Drug Pricing 220

PharmaTech

NOVEMBER 8, 2023

Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation, considers that status of oligonucleotides on the market.

98

98

STAT

NOVEMBER 8, 2023

Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today is coconut rum — and get started. To help you along, we have assembled another laundry list of items of interest for you to peruse.

Drug Pricing 168

Drug Pricing 168

European Pharmaceutical Review

NOVEMBER 8, 2023

A paper published by Research Square has described a rapid, simple, accurate and precise high-performance liquid chromatography with diode-array detection (HPLC-DAD) method for levofloxacin determination in liquid pharmaceutical formulations. The effectiveness of levofloxacin can be impacted by its stability in pharmaceutical formulations. This impacts the effective concentration of the drug, Mohammed et al. noted.

Dosage 92

Dosage 92

Express Pharma

NOVEMBER 8, 2023

The market for myasthenia gravis (MG), an autoimmune and neuromuscular disease characterised by muscle weakness and fatigue, is set to experience a compound annual growth rate (CARG) of 8.3 per cent across the seven major markets (7MM*) from $3 billion in 2022 to $6.7 billion in 2032, forecasts GlobalData. GlobalData’s latest report, “Myasthenia Gravis: Opportunity Assessment and Forecast,” identified the influx of several new disease-modifying therapies (DMTs) within the past two years as th

Labelling 90

Labelling Compounding 90

European Pharmaceutical Review

NOVEMBER 8, 2023

For UK patients with severe insomnia, for whom existing therapies have not worked, a new, decentralised clinical trial is set to evaluate chloral hydrate as a short-term treatment. Evaluating chloral hydrate for insomnia While chloral hydrate is already an established treatment for insomnia, much of the published clinical data in adult patients is dated, according to clinical trials company Lindus Health and global lifecycle management healthcare company Pharmanovia.

Dosage 91

Dosage 91

Outsourcing Pharma

NOVEMBER 8, 2023

myTrialsConnect, a research community powered by artificial intelligence (AI) has been launched following a partnership between Elligo Health Research and Avallano.

85

85

Pharmaceutical Commerce

NOVEMBER 8, 2023

Session explores how on-market products have done, and what to expect from new biosimilars.

Biosimilars 105

Biosimilars 105

pharmaphorum

NOVEMBER 8, 2023

Paywalls threaten healthcare professional engagement on social media Mike.

106

106

World Pharma News

NOVEMBER 8, 2023

An investigational therapy for solid tumors could be especially effective when combined with immunotherapy to target a specific kind of cancer cell, a research team at Duke and Harvard have found. Led by Lee Zou, Ph.D., chair of Duke’s Department of Pharmacology & Cancer Biology, the researchers focused on the way some cancer cells impede normal DNA repair to fuel tumor formation.

73

73

PharmExec

NOVEMBER 8, 2023

Companies must determine the right ways to utilize AI.

115

115

BioPharma Dive

NOVEMBER 8, 2023

CEO Chris Viehbacher said the company has “the elements to think about a return to topline growth.” Yet, that goal hinges on the successful commercialization of multiple new products.

62

62